Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0L1GI
|
||||
| Former ID |
DIB016467
|
||||
| Drug Name |
ReS8-T compounds
|
||||
| Synonyms |
Alzheimer program (tau-mediated cytotoxicity); Alzheimer program (tau-mediated cytotoxicity), reMYND; Tau detoxifying compounds (Alzheimer's), reMYND; Alzheimer program (tau-mediated cytotoxicity), reMYND/ Roche; ReS10-T compounds (Alzheimer's), reMYND; ReS19-T compounds (Alzheimer's), reMYND; ReS3-T compounds (Alzheimer's), reMYND; ReS8-T compounds (Alzheimer's), reMYND
|
||||
| Indication | Alzheimer disease [ICD9: 331; ICD10:G30] | Investigative | [531616] | ||
| Company |
ReMYND NV
|
||||
| Target and Pathway | |||||
| Target(s) | Microtubule-associated protein tau | Target Info | Modulator | [531616] | |
| KEGG Pathway | MAPK signaling pathway | ||||
| Alzheimer's disease | |||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| EGFR1 Signaling Pathway | |||||
| Pathway Interaction Database | LPA receptor mediated events | ||||
| Reelin signaling pathway | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.